
The Valuation Analyst
3.5K posts

The Valuation Analyst
@ValuationEdge_
📊 Fundamental & Technical Analyst 🧠 I help investors cut through noise → better decisions ⚠️ Not financial advice








4Q was a record quarter to cap a record year 📈 ✔️ Our 18th straight “beat and raise” ✔️ $395M revenue, an increase of 25% Y/Y (28% growth when excluding revenue from political candidates, LiveIntent and Marigold's Enterprise Business) ✔️ Highest-ever adj. EBITDA and FCF margins ✔️ Positive GAAP net income ✔️ Above the “rule of 50” again, and more With our proprietary data that improves with every customer interaction, intelligence that sharpens with every decision, and Athena by Zeta™ expected to become the interface that lowers the barriers to enterprise-wide adoption, we are positioned to be the AI disruptor in enterprise marketing software. Shoutout to our incredible Team Zeta for driving another quarter of growth! Learn more about our 4Q and full-year 2025 earnings results: businesswire.com/news/home/2026…










I wouldn’t be surprised at all if healthcare ends up leading in 2026. While everyone has been focused on AI and mega-cap tech, healthcare has quietly been resetting. Valuations have compressed. Sentiment is weak. Expectations are low. That’s usually where leadership starts. $UNH and $OSCR in particular look interesting to me. $UNH is a cash-flow machine with scale, data, and diversification across insurance and care delivery. It’s not flashy, but it compounds. $OSCR is higher beta, but it’s building a tech-driven insurance model in a massive market. If execution continues and margins improve, the upside could surprise people. Both are positioned well long term. If capital rotates out of crowded trades and into overlooked sectors, healthcare could have a big year. Sometimes the best opportunities aren’t the loudest ones.









